Cargando…

Rationally Designed Chimeric Antibodies for COVID-19 and Future Coronavirus Variants

Detalles Bibliográficos
Autores principales:	Hsueh, Ching-chung, Plotkin, Steven S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Biophysical Society 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879970/ http://dx.doi.org/10.1016/j.bpj.2020.11.390

Ejemplares similares

Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD
por: Li, Yulei, et al.
Publicado: (2023)

Biophysically Inspired Rational Design of Structured Chimeric Substrates for DNAzyme Cascade Engineering
por: Lakin, Matthew R., et al.
Publicado: (2014)

A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease
por: Gibbs, Ebrima, et al.
Publicado: (2019)

Rational Generation of Monoclonal Antibodies Selective for Pathogenic Forms of Alpha-Synuclein
por: Gibbs, Ebrima, et al.
Publicado: (2022)

A Mathematical Model for the Rational Design of Chimeric Ligands in Selective Drug Therapies
por: Doldán-Martelli, V, et al.
Publicado: (2013)

The Future of Synbiotics: Rational Formulation and Design
por: Gomez Quintero, David F., et al.
Publicado: (2022)

Rational Design and Biotechnological Production of Novel AfpB-PAF26 Chimeric Antifungal Proteins
por: Heredero, Marcos, et al.
Publicado: (2018)

Rationalization and Design of the Complementarity Determining Region Sequences in an Antibody-Antigen Recognition Interface
por: Yu, Chung-Ming, et al.
Publicado: (2012)

Mechanistic insights into the rational design of masked antibodies
por: Orozco, Carolina T., et al.
Publicado: (2022)

Rational Vaccine Design in the Time of COVID-19
por: Burton, Dennis R., et al.
Publicado: (2020)

Molecular targets for the rational design of drugs to inhibit SARS coronavirus
por: Brockway, Sarah M., et al.
Publicado: (2004)

Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against Pseudomonas aeruginosa
por: Wan, Chuang, et al.
Publicado: (2019)

Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats
por: Fernández-Quintero, Monica L., et al.
Publicado: (2022)

Rational Design of Chemically Controlled Antibodies and Protein Therapeutics
por: Marchand, Anthony, et al.
Publicado: (2023)

The immunogenicity of chimeric antibodies
Publicado: (1989)

Rational hand hygiene during the coronavirus 2019 (COVID-19) pandemic
por: Cavanagh, Gregory, et al.
Publicado: (2020)

A Rational Designed Novel Bispecific Antibody for the Treatment of GBM
por: Sun, Rui, et al.
Publicado: (2021)

Corrigendum: Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats
por: Fernández-Quintero, Monica L., et al.
Publicado: (2022)

Rational Design of CXCR4 Specific Antibodies with Elongated CDRs
por: Liu, Tao, et al.
Publicado: (2014)

Rational Design of a Pan-Coronavirus Vaccine Based on Conserved CTL Epitopes
por: Li, Minchao, et al.
Publicado: (2021)

Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines
por: Du, Lanying, et al.
Publicado: (2016)

Design and Construction of Chimeric VP8-S2 Antigen for Bovine Rotavirus and Bovine Coronavirus
por: Nasiri, Khadijeh, et al.
Publicado: (2016)

Rational design of a conformation-specific antibody for the quantification of Aβ oligomers
por: Aprile, Francesco A., et al.
Publicado: (2020)

Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID-19 therapy
por: Wong, Henry Sung-Ching, et al.
Publicado: (2021)

An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity
por: Maus, Marcela V, et al.
Publicado: (2017)

Coronavirus Non-Structural Protein 1 Is a Major Pathogenicity Factor: Implications for the Rational Design of Coronavirus Vaccines
por: Züst, Roland, et al.
Publicado: (2007)

Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae
por: Ma, Zhiqian, et al.
Publicado: (2020)

Rational design of bifunctional conjugated microporous polymers
por: Song, Yanpei, et al.
Publicado: (2021)

The rational design of vaccines
por: Bramwell, Vincent W., et al.
Publicado: (2005)

Protein engineering approaches for antibody fragments: directed evolution and rational design approaches
por: ARSLAN, Merve, et al.
Publicado: (2019)

Reviewing Ligand-Based Rational Drug Design: The Search for an ATP Synthase Inhibitor
por: Lee, Chia-Hsien, et al.
Publicado: (2011)

Rational In Silico Design of Molecularly Imprinted Polymers: Current Challenges and Future Potential
por: Rajpal, Soumya, et al.
Publicado: (2023)

Rational antibody design for undruggable targets using kinetically controlled biomolecular probes
por: Trkulja, Carolina L., et al.
Publicado: (2021)

P1212: RATIONALLY DESIGNED CHIMERIC PI3K-BET BROMODOMAIN INHIBITORS ELICIT CURATIVE RESPONSES IN MYC-DRIVEN LYMPHOMA
por: Oh, Danielle H., et al.
Publicado: (2023)

Rational drug design
por: Truhlar, Donald, et al.
Publicado: (1999)

A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer
por: Huang, Jing, et al.
Publicado: (2020)

Manipulation of the Coronavirus Genome Using Targeted RNA Recombination with Interspecies Chimeric Coronaviruses
por: de Haan, Cornelis A.M., et al.
Publicado: (2007)

COVID vaccine efficacy against the B.1.351 (“South African”) variant—The urgent need to lay the groundwork for possible future challenge studies
por: Eyal, Nir, et al.
Publicado: (2021)

Sleeping Beauty transposase structure allows rational design of hyperactive variants for genetic engineering
por: Voigt, Franka, et al.
Publicado: (2016)

REP-X: An Evolution-guided Strategy for the Rational Design of Cysteine-less Protein Variants
por: Dalton, Kevin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s461t10lp230m6pbrmpirjq19p